Wells Fargo & Company Summit Therapeutics Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 200 shares of SMMT stock, worth $4,022. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 34,082
99.41%
Holding current value
$4,022
Previous $265,000
98.49%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding SMMT
# of Institutions
211Shares Held
76.5MCall Options Held
2MPut Options Held
2.83M-
Baker Bros. Advisors LP New York, NY24.4MShares$491 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$220 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$159 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$109 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$69.8 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.05B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...